drugset / Trial / NCT01046799

Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir

NCT01046799

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether hepatitis B immunoglobin can be discontinued early after hepatitis B virus (HBV) induced liver transplantation and be replaced by the nucleoside analogue entecavir to prevent hepatitis B reinfection.

Timeline

Start
2008-03
Primary completion
2014-06
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Entecavir Small molecule